Clinical Trial Update: An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating mitiperstat (AZD4831), an MPO inhibitor, versus placebo in moderate-to-severe chronic obstructive pulmonary disease has completed, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Mitiperstat (AZD4831) (mitiperstat)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2025-08-29